Description
Three-year follow-up data of ELOQUENT-2: sustained benefit of elotuzumab in patients with relapsed/ refractory multiple myeloma
Article: Three-year follow-up data of ELOQUENT-2: sustained benefit of elotuzumab in patients with relapsed/ refractory multiple myeloma
€2.42
Related products
-
Article: Highlights in squamous cell carcinoma of the head and neck
€2.42 Add to cart -
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€2.42 Add to cart -
Article: INTRODUCTION
€2.42 Add to cart -
Article: Highlights in breast cancer
€2.42 Add to cart
